A vicious partnership between AKT and PHLDA 3 to facilitate neuroendocrine tumors

Abstract excerpt

Pancreatic neuroendocrine tumors (PanNET) are rare cancers that generally have a poor prognosis. Accurate diagnosis and proper treatment of these tumors requires a better understanding of the molecular mechanisms underlying the development of PanNET. It has been shown that the mTOR inhibitor everolimus can improve the progression‐free survival of PanNET patients, suggesting that inhibition of the PI3K‐Akt‐mTOR...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gestational Trophoblastic Disease Studies
• Share to Lung Cancer Research Studies
• Share to Neuroendocrine Tumor Research Advances